Website: https://symmera.com/
Type of Company: Software & application
Company Status: Active
Business: Symmera provides a SaaS platform for digital trust helping application developers, device manufacturers, and end-users empower AI/ML engines with cyber-safe devices and trusted data for data-driven insights and analytics.
Outcome:
Co-investors: Individuals and founders
Boulder, CO – December 10th, 2024 – Ambrosia Biosciences Inc. (“Ambrosia”), today announced the successful second closing of its Series A financing. This closing was led by Merck, known as MSD outside the United States and Canada, with additional participation from existing investors BVF Partners and Boulder Ventures. This additional capital brings Ambrosia’s total Series A financing to $25MM.
SAN JOSE, CA, USA, December 10, 2024 /EINPresswire.com/ — PeopleReign, the industry-leading SaaS platform that automates IT and HR employee service, today announced 600% year over year annually recurring revenue (ARR) growth thanks to increasing adoption of its System of Intelligence AI platform that gives every employee back four to six hours of productive time per week.
Armando Menocal, a Cuban-American civil rights lawyer and passionate climber who played a pivotal role in securing and preserving climbing access across the United States and Latin America, passed away on October 20, 2024, after a battle with lung cancer. He was 83.
A tireless advocate for climbers, he dedicated decades of his life to ensuring the sport remained accessible and minimally regulated. He is survived by his wife, Laura Rodriguez; his three sons, Matt, Diego, and Luis Manuel; his grandchildren, Alejandro, Ariel, Sierra, Wyatt, and Amelia; and his beloved dog, Wasabi. His son Marshall predeceased him in 2023.
OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the completion of its previously announced merger of OnKure, Inc. and Reneo Pharmaceuticals, Inc. (“Reneo”). The combined company will operate under the name OnKure Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on October 7, 2024 under the ticker symbol “OKUR”.
uMotif – one of the clinical research technology market’s fastest-growing companies – has acquired site platform provider ClinOne. The acquisition expands uMotif’s existing strengths in improving both the site and patient journey.
